Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, is making strides in the development and commercialization of therapeutics to transform radiotherapy in cancer patients. The Pennsylvania-based company is focused on its lead product candidate, avasopasem manganese (GC4419), a small molecule dismutase mimetic. The product has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC), in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer, and another in Phase IIa clinical trial for HNC patients undergoing standard-of-care radiotherapy. Galera Therapeutics is also developing GC4711, a dismutase mimetic product candidate, which is currently in Phase I/II clinical trial for use in combination with stereotactic body radiation therapy in patients suffering from non-small cell lung cancer and locally advanced pancreatic cancer. The company, founded in 2012, is dedicated to transforming the lives of cancer patients with its groundbreaking therapies.
Galera Therapeutics, Inc.'s ticker is GRTX
The company's shares trade on the NASDAQ stock exchange
They are based in Malvern, Pennsylvania
There are 11-50 employees working at Galera Therapeutics, Inc.
It is https://www.galeratx.com/
Galera Therapeutics, Inc. is in the Healthcare sector
Galera Therapeutics, Inc. is in the Biotechnology industry
The following five companies are Galera Therapeutics, Inc.'s industry peers: